OPPS Comments Focus on Observation Status
Comments generally favored the CMS proposal to reimburse hospitals for separately payable drugs and biologicals without pass-through status at average sales price plus 6%.
The move has the strong support of the AHA, which commented that the change "would improve stability of drug and biological payments" and is less cumbersome that the current system which "involves complex calculations and an annual overhead adjustment in which costs are redistributed from packaged drugs to separately payable drugs."
American Academy of Otolaryngology also supports the change, which "more accurately reflect the actual costs incurred by hospitals in providing and administering drugs and biologics."
CMS is expected to release the final OPPS rule in November.
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- How the Military's EHR Reboot Will Impact Interoperability
- HCA to Acquire CareNow Urgent Care Centers
- BCBS Tries New Drug Contracting Model
- Federal Appeals Court Mulls Observation Status
- Abington Health, Jefferson Health Plan '100% Equal' Merger
- Dental Board Case Before SCOTUS Has Far-Reaching Implications
- How One Health System Saved $3.5M in Benefits Costs
- The Case for Recycling Surgical Supplies
- 76% of Physicians Don't Like CMS Quality Reporting Programs
- Ballot Initiative Pits Providers Against Payers in SD